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Inducible Nitric Oxide Synthase Induction Underlies
Lipid-Induced Hepatic Insulin Resistance in Mice
Potential Role of Tyrosine Nitration of Insulin Signaling
Proteins
Alexandre Charbonneau and Andre ´ Marette
OBJECTIVE—The present study was undertaken to assess the
contribution of inducible nitric oxide (NO) synthase (iNOS) to
lipid-induced insulin resistance in vivo.
RESEARCH DESIGN AND METHODS—Wild-type and
iNOS
/ mice were infused for 6 h with a 20% intralipid emul-
sion, during which a hyperinsulinemic-euglycemic clamp was
performed.
RESULTS—In wild-type mice, lipid infusion led to elevated
basal hepatic glucose production and marked insulin resistance
as revealed by impaired suppression of liver glucose production
and reduced peripheral glucose disposal (Rd) during insulin
infusion. Liver insulin resistance was associated with a robust
induction of hepatic iNOS, reduced tyrosine phosphorylation of
insulin receptor (IR) , insulin receptor substrate (IRS)-1, and
IRS-2 but elevated serine phosphorylation of IRS proteins as well
as decreased Akt activation. The expression of gluconeogenic
enzymes Pepck and G6Pc was also increased in the liver of
wild-type mice. In contrast to their wild-type counterparts,
iNOS
/ mice were protected from lipid-induced hepatic and
peripheral insulin resistance. Moreover, neither the phosphory-
lation of insulin signaling intermediates nor expression of glu-
coneogenic enzymes were altered in the lipid-infused iNOS
/
mice compared with their saline-infused controls. Importantly,
lipid infusion induced tyrosine nitration of IR, IRS-1, IRS-2, and
Akt in wild-type mice but not in iNOS
/ animals. Furthermore,
tyrosine nitration of hepatic Akt by the NO derivative peroxyni-
trite blunted insulin-induced Akt tyrosine phosphorylation and
kinase activity.
CONCLUSIONS—These ﬁndings demonstrate that iNOS induc-
tion is a novel mechanism by which circulating lipids inhibit
hepatic insulin action. Our results further suggest that iNOS may
cause hepatic insulin resistance through tyrosine nitration of key
insulin signaling proteins. Diabetes 59:861–871, 2010
I
n recent years, the complex interplay occurring
between immunity and energy metabolism has be-
come increasingly evident as a growing number of
factors once thought to be of sole importance for
immune function have been shown to play essential roles
in the regulation of glucose and lipid metabolism (1,2).
One such molecule is the inducible nitric oxide (NO)
synthase (iNOS). First identiﬁed for its vital role in immu-
nity, iNOS is now known to be expressed in metabolic
tissues under various conditions of metabolic stress and
has been implicated in the pathogenesis of obesity-linked
insulin resistance and -cell failure (1,2). Our laboratory
ﬁrst demonstrated that genetic deletion of iNOS protects
against high-fat diet (HFD)-induced insulin resistance (1).
We found that protection against obesity-linked insulin
resistance in skeletal muscle was sufﬁcient to improve
whole-body insulin sensitivity and glucose tolerance in
high-fat–fed iNOS
/ mice (knockout). This was linked to
the normalization of the insulin-induced phosphoinositide
3-kinase (PI3K)/Akt pathway in muscle of obese knockout
mice as compared with their wild-type counterparts. Fur-
ther studies conﬁrmed that iNOS is a potential target for
alleviating the adverse effects of obesity on insulin’s
glucoregulatory actions and vascular insulin resistance
(3,4). Our group has also shown that iNOS-derived NO not
only inﬂuences the activity of proximal components of the
insulin signaling pathway (1,5,6) but also modulates the
transcription of metabolic genes through the intricate
regulation of peroxisome proliferator–activated receptor 
activity (7).
Additional examples of immuno-metabolic crossovers
are apparent in the mechanisms by which free fatty acids
(FFAs) induce insulin resistance. Indeed, short-term lipid
infusion can impede insulin action in liver and skeletal
muscle along with an accompanying inﬂammatory re-
sponse (8). Recent studies (9–11) suggest that elevated
circulating FFAs may exert their proinﬂammatory and
insulin-desensitizing effects by binding to toll-like recep-
tors. This interaction activates intracellular inﬂammatory
signaling pathways that impinge on key components of the
insulin signaling cascade. Although our understanding of
the inﬂammatory mechanisms underlying FFA-induced
insulin resistance has evolved in recent times, the detri-
mental role of iNOS in this metabolic impairment has yet
to be investigated.
FFA-induced hepatic insulin resistance is often charac-
terized by multiple serine and tyrosine phosphorylation
defects on insulin receptor  (IR), IRS-1, IRS-2, and Akt.
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production due to an overactivation of phosphoenulpyru-
vate carboxykinase (Pepck) and glucose-6-phosphatase
(G6pc). These enzymes are transcriptionally regulated by
insulin via peroxisome proliferator–activated receptor-
coactivator (PGC)-1- and Forkhead box-O1 transcription
factor (FoxO1) (12). Interestingly, no studies have ex-
plored the possible link between iNOS and the transcrip-
tional regulation of glucose production in liver insulin
resistance.
In the present study, we tested the hypothesis that
hepatic iNOS induction underlies lipid-induced insulin
resistance in liver and skeletal muscle. Using a murine
model of short-term lipid infusion to create conditions
where FFAs alone are sufﬁcient to induce insulin resis-
tance, we present data that clearly support a causal role
for hepatic iNOS in lipid-induced alterations in glucose
metabolism and insulin action in vivo. Our results also
uncover iNOS-dependent tyrosine nitration of IR, IRS,
and Akt proteins as a potential novel mechanism whereby
lipids regulate hepatic insulin action.
RESEARCH DESIGN AND METHODS
Experiments were performed using 8- to 12-week-old male C57BL/6 mice
(wild-type) and iNOS
/ (knockout) mice (Nos2tm1Lau;C57BL/6 back-
crossed) purchased from The Jackson Laboratory (Bar Harbor, ME). Animals
were maintained in pathogen-free conditions and housed individually in a
temperature-controlled environment under a 12-h light cycle. Animals were
placed on a rodent diet (Harlan Teklad, Madison, WI) and given free access to
food and water. All protocols were in accordance with the Canadian Council
on Animal Care.
Paired infusion hyperinsulinemic-euglycemic clamp procedure. Wild-
type and knockout mice were randomly assigned to either saline or 20%
intralipid (20% soybean oil, 1.2% egg phospholipids, and 2.2% glycerin)
infusion groups. Five days prior to the experiment, mice were anesthetized
and catheters inserted into the left common carotid artery and the right
jugular vein for blood sampling and infusions, respectively. The free catheter
ends were tunneled under the skin, externalized at the neck, and sealed. Mice
were fasted for 5 h before the clamp procedure. The intravenous infusion
catheters were connected to a swivel 1 h prior to the infusion, and the mice
were unrestrained and not handled thereafter to minimize stress. Before the
onset of the infusion protocol (t  10 min), blood samples were obtained to
determine preinfusion FFA levels. At t  0 min, the 6-h saline (5 ml  kg
1 h
1)
or intralipid (5 ml  kg
1 h
1) (Baxter, Ontario, Canada) infusion protocol
with 20 IU/ml heparin (LEO Pharma, Ontario, Canada) was initiated (t 
0–360 min). Two and a half hours into the infusion (t  150 min), the
hyperinsulinemic-euglycemic clamp (HIEC) was initiated according to previ-
ously described methodology (13). At the end of the clamp, mice were
anesthetized, cardiac punctures were performed, and liver and hindlimb
muscles were excised, freeze-clamped, and stored at 80°C until further
analyses.
Calculations. Hepatic glucose production and peripheral Rd were deter-
mined using Mari’s non–steady-state equations (14). Clamp glucose produc-
tion was determined by subtracting the glucose infusion rate (GIR) from total
glucose production.
Akt kinase assay. Procedures were performed according to Tremblay et al.
(15) as detailed in the supplementary methodology, which can be found in the
online appendix (available at http://diabetes.diabetesjournals.org/cgi/content/
full/db09-1238/DC1).
Protein extraction, immunoprecipitation, and immunoblotting analyses.
Livers and gastrocnemius muscles were processed as previously described (7)
and detailed in supplementary methodology and supplementary Table 1
(online appendix).
RNA extraction and Q-PCR. Total RNA was isolated from liver samples as
previously described (7) as detailed in the supplementary methodology.
Brieﬂy, G6Pc, Pepck, and -actin were measured using 50 ng of each of the
following primer pairs: G6pc:5 -GCTTGGATTCTACCTGCTAC-3 and 5-
AAAGACTTCTTGTGTGTCTGTC-3; Pepck:5 -CCACAGCTGCTGCAGAACA-
3 and 5-AAAGACTTCTTGTGTGTCTGTC-3; and -actin:5 -CTAGAAG-
CACTTGCGGTGCAC-3 and 5-GAAATCGTGCGTGACATCAAA-3.
Analytical methods. Plasma insulin was assessed by radioimmunoassay
(Linco, St. Charles, MO). FFAs were measured by colorimetric assay (Wako
Chemicals, Richmond, VA). NO2
 concentrations were assessed with a
DAN/NaOH-based kit (Cayman Chemical, Ann Arbor, MI). Liver glycogen was
determined using the phenolsulphuric acid reaction (16). Plasma [3-
3H]glu-
cose was determined as previously described (13).
Peroxynitrite treatment and hepatic Akt tyrosine nitration and phos-
phorylation. Wild-type mice were injected (intravenously) with saline or
insulin (4 units/kg) for 5 min, and the liver was excised and homogenized as
described above. Lysates were immunoprecipitated with antibodies speciﬁc
for Akt and treated with 50 mol/l of peroxynitrite (ONOO
) or decomposed
peroxynitrite (dONOO
) for 2 min (Millipore, San Francisco, CA) according to
previously described methodology (17,18). dONOO
 was obtained by allowing
peroxynitrite to decompose overnight in lysate buffer. Subsequently, lysates
were subjected to immunoblot analysis as described above.
Statistical analysis. All data are reported as means  SE. Statistical
comparisons were performed using a two-way ANOVA for nonrepeated-
measures design. Newman-Keuls post hoc test was used in the event of a
signiﬁcant (P 	 0.05) F ratio.
RESULTS
Short-term intralipid infusion promotes iNOS ex-
pression and NO production in vivo. To establish the
role of iNOS in the metabolic effects of elevated FFAs, we
examined whether a 6-h intralipid infusion was sufﬁcient
to induce iNOS expression and accumulation of the NO
derivative nitrite (NO2
) in liver and skeletal muscle.
Immunoblot analysis of hepatic iNOS protein levels in
wild-type mice showed a robust (approximately threefold)
induction following intralipid infusion (P 	 0.05) com-
pared with saline-infused controls (Fig. 1A). iNOS induc-
tion was associated with heightened NO2
 accumulation
(
2.2-fold) in the liver of intralipid-infused wild-type mice
(P 	 0.05) (Fig. 1C). This is the ﬁrst report that short-term
lipid exposure is sufﬁcient to induce iNOS and NO produc-
tion in liver. In contrast to liver, intralipid infusion caused
nonsigniﬁcant iNOS induction in skeletal muscle. How-
ever, intralipid infusion increased muscle iNOS activity, as
revealed by a signiﬁcant accumulation of NO2
 (
1.6-fold,
P 	 0.05) in skeletal muscle of wild-type mice but not in
their knockout counterparts (Fig. 1B–D).
Role of iNOS in lipid-induced modulation of plasma
glucose and insulin. The glucoregulatory inﬂuence of
iNOS induction in lipid-challenged wild-type and knockout
mice was determined during an HIEC. Physiological pa-
rameters measured at preinfusion, preclamp, and during
the HIEC are shown in Table 1. No effect of iNOS genetic
deletion was observed on any of the parameters measured
prior to the infusion protocol. As expected, prior to the
clamp, intralipid infusion led to a marked increase in
plasma FFAs in both wild-type and knockout mice com-
pared with their saline-infused counterparts (P 	 0.05).
Insulin infusion during the clamp led to a reduction in
plasma FFAs in all groups. It is noteworthy that the
magnitude of the intralipid-induced rise in plasma FFAs
was comparable among the wild-type and knockout mice.
Nevertheless, lack of iNOS prevented intralipid-induced
elevations in both blood glucose and insulin concentra-
tions. Indeed, intralipid-infused wild-type mice displayed
signiﬁcantly elevated glycemia (preclamp) compared with
the corresponding knockout mice (P 	 0.05). Further-
more, plasma insulin rose signiﬁcantly after 150 min in
lipid-infused wild-type mice compared with their saline-
infused controls (P 	 0.05). Since neither glycemia nor
insulinemia varied among infusion groups in the knockout
mice, these data provide initial evidence that iNOS plays a
role in the lipid-induced perturbations of glucose metabo-
lism in vivo. As expected, hepatic glycogen levels were
decreased in lipid-infused animals (Table 1), and this
parameter was independent of the genotype.
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insulin resistance. The HIEC was performed in unison
with the intralipid infusion to assess differences in whole-
body insulin sensitivity and to deﬁne the contribution of
the liver and skeletal muscle to insulin’s metabolic re-
sponses. GIR, glucose production, and Rd were assessed
with arterial glycemia and insulinemia clamped at 6–7
mmol/l and 150–170 U/ml, respectively (Table 1). As
suggested by the observed perturbations in preclamp
glycemia and insulinemia, the HIEC data showed that
intralipid infusion causes insulin resistance in wild-type
mice, while knockout animals are protected from this
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FIG. 1. Lipid infusion increases iNOS expression and NO production in liver and skeletal muscle. Immunoblots (IB) for iNOS (A and B) and nitrite
concentrations (C and D) in liver and gactrocnemius extracts of wild-type (WT) and iNOS
/ (KO) mice following an HIEC performed during the
l a s t2ho fa6 - hsaline or lipid infusion in 5-h fasted, chronically catheterized, conscious mice at least 5 days following surgical procedure. A and
B: Immunoblottings of tissue lysates were performed with iNOS antibody, and densitometric analyses were normalized for the expression of
tubulin content in the same sample. Lanes were run on the same gel but were noncontiguous. Data are means  SE. Interactions between groups;
*P < 0.05 vs. saline counterpart.
TABLE 1
Basal and clamp characteristics in wild-type and iNOS
/ mice following a 6-h treatment of either saline or intravenous infusion of
intralipid
Wild type Knockout
Saline Intralipid Saline Intralipid
n 6666
Weight (g) 24.0  0.9 25.2  1.1 24.5  1.3 23.9  1.4
Blood glucose (mmol/l)
Basal 6.3  0.4 6.9  0.2 5.8  0.2 6.1  0.1†
Clamp 6.9  0.4 6.6  0.3 6.7  0.3 6.9  0.4
Insulin (U/ml)
Basal 15.9  4.2 20.4  2.5* 16.5  3 15.7  3.5
Clamp 155  27 164  29 167  29 173  33
FFA (mEq/l)
Preinfusion 0.69  0.08 0.71  0.09 0.60  0.07 0.61  0.07
Basal 0.61  0.07 1.11  0.1* 0.56  0.08 1.05  0.3*
Clamp 0.26  0.03 0.72  0.06* 0.28  0.05 0.69  0.22*
Glycogen (mg/g liver) 79.2  6.4 40.0  7.6* 74.2  7.1 45.2  12.4*
Data are means  SE. *P 	 0.05 vs. saline counterpart; †P 	 0.05 vs. wild type.
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was reduced by 
24% (P 	 0.05) in lipid-infused wild-type
mice compared with saline-infused animals (Fig. 2A),
whereas the GIR of lipid-infused knockout mice did not
vary from that of their saline-infused counterparts. In line
with iNOS induction, the liver appears to be the primary
site of perturbed glucose metabolism in this short-term
intralipid infusion model. Indeed, basal glucose produc-
tion was elevated by 
45% (P 	 0.05) (Fig. 2B) and
insulin-mediated suppression of glucose production was
impaired by 
46% (P 	 0.05) (Fig. 2C and D) in lipid-
infused wild-type mice. Although basal Rd was not affected
by intralipid infusion, we did observe an 
15% reduction
(P 	 0.05) in insulin-mediated Rd during the clamp in
wild-type mice (Fig. 2E and F). Importantly, knockout
mice were protected against lipid-induced liver and mus-
cle insulin resistance, providing genetic evidence that
iNOS is a mediator of lipid-induced insulin resistance in
both tissues.
iNOS is key to lipid-induced perturbations in hepatic
insulin signaling proteins. Since the effects of intralipid
infusion on iNOS and glucose metabolism were most
pronounced in liver, we chose to explore the mechanisms
underlying lipid-induced insulin resistance in this tissue.
We ﬁrst assessed the impact of lipid-induced iNOS expres-
sion on the phosphorylation state of IR, IRS-1, and IRS-2,
key transducers of insulin’s metabolic actions in liver (19).
Immunoblot analysis showed that tyrosine phosphoryla-
tion of both IR and IRS-2 is signiﬁcantly diminished in
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FIG. 2. HIEC characteristics in saline and lipid-infused wild-type (WT) and iNOS
/ (KO) mice. Glucose infusion rate (A), basal glucose
production (B), clamp glucose production (C), percentage of glucose production suppression (D), basal (E), and clamp (F) whole-body glucose
uptake during an HIEC performed as described in the legend to Fig. 1. Data are means  SE. Interactions between groups; *P < 0.05 vs. saline
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infused controls (P 	 0.05) (supplementary Fig. 1A and
Fig. 3A). Tyrosine phosphorylation of IRS-1 also tended to
be reduced in these mice (Fig. 3B). Importantly, tyrosine
phosphorylation of all three proteins was found to be
greater in lipid-infused knockout mice compared with
their wild-type counterparts (P 	 0.05) (supplementary
Fig. 1A and Fig. 3A and B).
In line with the lipid-induced reduction in IRS-1/-2
tyrosine phosphorylation, lipid-infused wild-type mice also
displayed elevated inhibitory phosphorylation of Ser133 in
IRS-2 and Ser307 in IRS-1 compared with their saline-
infused controls (P 	 0.05) (Fig. 3C and D). In contrast to
tyrosine phosphorylation, serine phosphorylation of IRS-1
and IRS-2 is known to inhibit downstream insulin signaling
(20). Interestingly, knockout mice were completely pro-
tected from these detrimental effects of intralipid infusion.
To determine whether the perturbations in phosphory-
lation of IR, IRS-1, and IRS-2 translated in reduced
downstream signaling, we examined Akt Ser473/Thr308
phosphorylation and kinase activity. We found that Akt
phosphorylation on Ser473 and Thr308 as well as Akt
kinase activity were reduced in lipid-infused wild-type
mice compared with saline-infused controls (P 	 0.05)
(supplementary Fig. 2A and Fig. 3E and F). Genetic
deletion of iNOS partially, but not signiﬁcantly, restored
Akt Thr308 phosphorylation in lipid-infused animals while
fully reversing impairments in both Akt Ser473 phosphor-
ylation and kinase activity, further suggesting a key role
for iNOS in the lipid-mediated inhibition of hepatic insulin
signaling.
iNOS is involved in the regulation of lipid-induced
elevations of hepatic gluconeogenesis. To gain a more
precise understanding of the role of iNOS in lipid-induced
elevations in glucose production, we studied transcrip-
tional regulators of hepatic gluconeogenesis, PGC1 and
FoxO1. In line with the elevated glucose production wit-
nessed during the clamp, PGC1 protein content was
increased in lipid-infused wild-type mice compared with
saline-infused controls (P 	 0.05) (Fig. 4A). Importantly,
iNOS genetic disruption prevented the rise in PGC1
protein expression in the lipid-infused knockout mice (P 	
0.05) (Fig. 4A). Phosphorylation of FoxO1 by Akt in
response to insulin is known to abolish FoxO1 binding to
PGC1, leading to reduced expression of the gluconeo-
genic genes Pepck and G6Pc (12). We found that FoxO1
phosphorylation on Ser256, a marker of its nuclear exclu-
sion and inactivation by Akt, was decreased in lipid-
infused wild-type mice as compared with saline-infused
controls (P 	 0.05) (Fig. 4B). However, this was not
observed in knockout animals where FoxO1 Ser256 phos-
phorylation was signiﬁcantly increased in liver of lipid-
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/ (KO) mice following an HIEC performed as described in the legend to Fig. 1. A and B: Immunoblottings of tissue
lysates were performed with PGC1 and pFoxO1 (Ser256) antibody, and densitometric analyses were normalized for the expression of tubulin
and FoxO1 content in the same sample, respectively. Lanes were run on the same gel but were noncontiguous. C and D: Pepck and G6Pc mRNA
expressions were evaluated by quantitative RT-PCR, and values were corrected for housekeeping -actin transcript levels. Data are means  SE.
Interactions between groups; *P < 0.05 vs. saline counterpart; †P < 0.05 vs. wild type.
iNOS AND LIPID-INDUCED INSULIN RESISTANCE
866 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orginfused knockout mice compared with their wild-type
counterparts.
In line with the regulation of PGC1 and FoxO1, in-
tralipid infusion increased the expression of Pepck and
G6Pc transcripts in wild-type mice compared with the
saline-infused controls (P 	 0.05) (Fig. 4C and D). In-
tralipid infusion also increased Pepck and G6Pc mRNA
expression in knockout mice but to a lesser extent com-
pared with their lipid-infused wild-type counterparts.
Taken together, these data are the ﬁrst to demonstrate a
role for iNOS in the transcriptional regulation of hepatic
gluconeogenesis in conditions of lipid excess.
iNOS modulates glucose production through tyrosine
nitration of IR, IRS, and Akt proteins. To further
explore the mechanisms underlying hepatic insulin resis-
tance in lipid-infused mice, we assessed whether insulin
signaling proteins were modiﬁed through iNOS-mediated
protein tyrosine nitration. Tyrosine nitration is a covalent
posttranslational protein modiﬁcation that is derived from
the reaction of proteins with nitrating agents such as
ONOO
, a potent oxidant derivative of NO (21). Tyrosine
nitration has been used as a biomarker of nitrosative
stress in several pathological conditions including insulin
resistance (21,22). Growing evidence suggests that this
modiﬁcation can alter protein function by preventing
functional phosphorylation (23–25). Since iNOS induction
promotes the generation of NO-derived ONOO
,w eh y -
pothesized that IRS-1/-2 tyrosine nitration could underlie
iNOS-dependent inhibition of IRS-1/-2 tyrosine phosphor-
ylation and hepatic insulin resistance in lipid-challenged
mice.
Since Akt activity is also regulated by the phosphoryla-
tion of key tyrosine residues (26), we also assessed
whether Akt is tyrosine nitrated in lipid-infused wild-type
mice. Immunoblot analysis of IR, IRS-1, IRS-2, and Akt
immunoprecipitates with a 3-nitrotyrosine antibody re-
vealed that tyrosine nitration of all four proteins were
signiﬁcantly increased in liver of lipid-infused wild-type
mice as compared with saline-infused controls (P 	 0.05)
(supplementary Fig. 1B and Fig. 5A–C). Akt tyrosine
nitration was associated with impaired kinase tyrosine
phosphorylation (Fig. 5D). Notably, iNOS gene disruption
signiﬁcantly reduced IR, IRS-1, and Akt tyrosine nitration
in liver of lipid-infused mice, suggesting that the inability
A B
C D
0
1
2
3
I
R
S
2
 
N
i
t
r
a
t
i
o
n
 
(
T
y
r
)
(
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
)
I
R
S
1
 
N
i
t
r
a
t
i
o
n
 
(
T
y
r
)
(
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
)
-185 kDa
*
†
-185 kDa IB: IRS2
IB:3-NT
IB:3-NT
IB:3-NT
SAL
WT KO
LIP
WT KO
0
1
2
3
4
5
*
*
,†
-180 kDa
-180 kDa IB: IRS1
SAL
WT KO
LIP
WT KO
0
1
2
p
 
A
K
T
 
(
T
y
r
)
(
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
)
*
*
,†
-60 kDa
-60 kDa
IB: AKT
IB:4G10
SAL
WT KO
LIP
WT KO
0
1
2
3
4
5
A
K
T
 
N
i
t
r
a
t
i
o
n
 
(
T
y
r
)
(
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
) *
*
,†
-60 kDa
-60 kDa
IB: AKT
SAL
WT KO
LIP
WT KO
FIG. 5. Effects of lipid infusion on hepatic IRS-2, IRS-1, Akt tyrosine nitration, and Akt tyrosine phosphorylation. Immunoblots (IB) for IRS-2
nitration (Tyr) (A), IRS-1 nitration (Tyr) (B), Akt nitration (Tyr) (C), and Akt tyrosine phosphorylation in liver extracts of wild-type (WT) and
iNOS
/ (KO) mice following an HIEC performed as described in the legend to Fig. 1. A–D: IRS-2, IRS-1, and Akt were immunoprecipitated and
subsequent immunoblots were performed with 3-NT antibody for IRS-2 (A), IRS-1 (B), and either 3-NT (C) or 4G10 (D) for Akt. Densitometric
analyses were normalized for the expression of IRS-2, IRS-1, Akt, and tubulin in the same sample. C: Lanes were run on the same gel but were
noncontiguous. Data are means  SE. Interactions between groups; *P < 0.05 vs. saline counterpart; †P < 0.05 vs. wild type.
A. CHARBONNEAU AND A. MARETTE
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 867of insulin to suppress glucose production in lipid-infused
wild-type mice is linked to iNOS-dependent tyrosine nitra-
tion of key insulin signaling proteins.
ONOO
 inhibits insulin-stimulated Akt activity through
tyrosine nitration. We next determined whether treat-
ment of liver Akt with ONOO
 ex vivo could trigger Akt
tyrosine nitration and impede Akt activity as seen in liver
extracts from lipid-infused wild-type mice. Akt was immu-
noprecipitated from liver lysates of saline or insulin-
treated mice and incubated with ONOO
 in vitro for 2 min.
ONOO
 treatment was found to increase Akt tyrosine
nitration while decreasing Akt Tyr/Ser473 phosphoryla-
tions and Akt kinase activity (Fig. 6A–D). Importantly,
these effects were not observed in control experiments
with dONOO
. It is noteworthy that although ONOO

treatment signiﬁcantly decreased phosphorylation of Akt
Ser473, it did not affect phosphorylation of Akt Thr308
(supplementary Fig. 3C), suggesting that the reactive NO
derivative does not interact nonspeciﬁcally with the hy-
droxyl moiety of any residues. These data demonstrate
that Akt kinase activity is modulated in a tyrosine nitra-
tion-dependent manner and strongly suggest that iNOS-
mediated tyrosine nitration of Akt is a novel mechanism of
hepatic insulin resistance upon intralipid infusion.
DISCUSSION
A pathogenic immune response to nutrient excess is
believed to be involved in the development of obesity-
linked insulin resistance (27). Indeed, lipid-induced insulin
resistance in muscle and liver is linked to overactivation of
inﬂammatory signaling pathways known to impede insulin
signal transduction (27–29). We and others have shown
that iNOS is overexpressed in metabolic tissues of both
dietary and genetic models of obesity and plays a pivotal
role in the pathogenesis of insulin resistance and glucose
intolerance (1,3,4,28). However, it remained unclear
whether increased lipid availability, in the absence of
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can induce iNOS expression and NO production in meta-
bolic tissues of nonobese animals. This is key to determin-
ing whether iNOS should be considered as a primary
candidate for triggering insulin resistance in obesity or as
a late-onset exacerbating factor in the complex inﬂamma-
tory sequelae that characterizes the obese state. Using the
paired-infusion HIEC procedure, we report that iNOS can
be induced within a few hours in liver and to a lesser
extent in muscle of lipid-infused wild-type mice. Using
iNOS
/ mice, we further show that iNOS underlies lipid-
induced insulin resistance in both liver and skeletal
muscle.
The present work also unravels a previously unrecog-
nized role for iNOS in the transcriptional regulation of
hepatic gluconeogenesis. iNOS disruption restored insu-
lin’s ability to suppress glucose production and prevented
lipid-induced elevations in basal glucose production that
account for the initial hyperglycemia seen in wild-type
mice. Since glycogen levels were unaffected by the ab-
sence of iNOS, this provides clear evidence that iNOS
induction is involved in the regulation of hepatic glucone-
ogenesis and not glycogenolysis in response to lipid avail-
ability in vivo. Importantly, we were able to tie the
physiological alterations of hepatic glucose metabolism
following iNOS induction to the intrinsic regulation of the
expression of the gluconeogenic enzymes Pepck and
G6Pc. Indeed, iNOS gene disruption prevented lipid-in-
duced increases in gluconeogenic gene expression as well
as defects in their transcriptional regulators. This is the
ﬁrst time that iNOS is reported to be involved in the
lipid-mediated increase in liver PGC1 expression, a well-
established mechanism of augmented gluconeogenic gene
expression in altered metabolic states (12). Our ﬁnding
that iNOS expression was associated with PGC1 induc-
tion may also suggest that NO can trigger an adaptative
metabolic response to chronic lipid excess in liver. Indeed,
it has previously been shown that NO promotes mitochon-
drial biogenesis by stimulating PGC1 induction (30). It is
therefore conceivable that the iNOS-NO-PGC1 axis coor-
dinates hepatic metabolism in lipid-challenged conditions
through stimulation of gluconeogenesis and a later in-
crease in mitochondriogenesis and FFA oxidation
capacity.
It has been previously reported that iNOS induction in
metabolic tissues and insulin target cells interferes with
the IR/IRS/PI3K/Akt insulin signaling pathway (1,5,6,28).
Accordingly, we found that iNOS impairs insulin action on
glucose production by altering insulin signaling to IR,
IRS-1/-2, and Akt. Indeed, iNOS
/ mice were protected
from lipid-induced inhibitory phosphorylation of IRS-1
Ser307 and IRS-2 Ser133, two well-established target sites
of Ser/Thr kinases known to be activated by lipids through
activation of inﬂammatory pathways (e.g., IB kinase–
nuclear factor kB, c-Jun NH2-terminal kinase, protein
kinase C) (8,31,32). Conversely, IR and IRS-1/-2 tyrosine
phosphorylation were preserved in liver of lipid-chal-
lenged iNOS
/ mice. Similarly, lack of iNOS prevented
the lipid-induced impairment in Ser/Tyr phosphorylation
of Akt observed in wild-type mice, resulting in normaliza-
tion of hepatic Akt kinase activity. Normalization of IR
and IRS-1/-2 signaling and Akt activation likely explains
the improved action of insulin to inhibit gluconeogenic
enzymes in liver of iNOS
/ mice, since phosphorylation
of the key transcription factor FoxO1, which is mediated
by Akt (33), was restored in lipid-infused knockout mice.
Taken together with the increased expression of PGC1,
these results suggest that iNOS is a key inﬂammatory
mediator linking excessive lipid levels to activation of the
gluconeogenic transcription program in the liver of models
of elevated FFAs. In future studies, it will be interesting to
determine whether iNOS increases hepatic gluconeogenic
enzymes by modulating the ability of PGC1 to target
O-GlcNAc transferase for GlcNAcylation of FoxO1, an-
other mechanism by which PGC1 serves as a transcrip-
tional coactivator of gluconeogenic enzymes (34).
The present data further suggest that iNOS activation in
lipid-infused mice may impede insulin signaling through
tyrosine nitration of key insulin signaling proteins. Ty-
rosine nitration is a major covalent posttranslational pro-
tein modiﬁcation and a marker of nitrosative stress in
several pathological disorders associated with iNOS induc-
tion (21,35–38). However, no studies have explored
whether protein tyrosine nitration regulates hepatic insu-
lin signaling and glucose metabolism in vivo. Our results
show that intralipid infusion leads to tyrosine nitration of
IR, IRS-1, and IRS-2, as well as Akt in liver of wild-type
mice. Importantly, iNOS
/ animals are protected from
these nitrosative modiﬁcations and exhibited improved
hepatic insulin sensitivity, strongly suggesting a key role
for iNOS in the tyrosine nitration of IRS-1/-2 and Akt
proteins in lipid-induced hepatic insulin resistance.
iNOS likely promotes tyrosine nitration of IR, IRS-1/-2,
and Akt proteins through ONOO
 formation (39). Indeed,
although the role of ONOO
 in causing protein tyrosine
nitration is still debated, it is still recognized as the most
efﬁcient mechanism for nitrating tyrosine residues under
biologically relevant conditions (21,25,39). In vitro studies
have showed that ONOO
 induces tyrosine nitration of
IRS-1 interfering with its tyrosine phosphorylation and
activation of downstream insulin signaling (40). To further
conﬁrm the functional impact of tyrosine nitration on the
insulin signaling pathway, we exposed immunopuriﬁed
Akt from liver of insulin-treated wild-type mice to ONOO
.
We found that ONOO
 robustly increased Akt tyrosine
nitration, leading to reduced Ser/Tyr phosphorylation and
inhibition of Akt kinase activity. Nitration of Tyr315 and
Tyr326, which are of critical importance for Akt activation
by growth factors (26), are likely targets of nitration in
these studies. On the other hand, the reduction of Ser473
phosphorylation by ONOO
-mediated tyrosine nitration
was somewhat unexpected. Phosphorylation of Ser473 in
the hydrophobic motif (HM:site 469–474) of Akt is con-
sidered crucial for activation of the enzyme by insulin (41).
Interestingly, Ser473 is immediately adjacent to a tyrosine
residue positioned at site 474. It is therefore tempting to
speculate that nitrated adducts on Tyr474 could displace a
phosphate on the adjacent Ser473 and contribute to defec-
tive hepatic Akt activity. Another possible mechanism that
could affect Akt activation is the potential nitration of
three tyrosine residues (sites 18, 26, and 38) in the
pleckstrin homology domain (PH: site 6–107), which
would impede Akt translocation to the plasma membrane.
Further mass spectrometry/proteomic studies are war-
ranted to delineate the precise tyrosine residues within
Akt that are targeted by iNOS-generated ONOO
 and to
demonstrate their functional signiﬁcance in models of
hepatic insulin resistance.
We considered the possibility that ONOO
 might also
directly nitrate serine residues but this is unlikely given
that ONOO
 is thought to only interact with protein
tyrosyl groups in tyrosine or sulfhydryl groups within
A. CHARBONNEAU AND A. MARETTE
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threonine residues contain tyrosyls or thiols. Accordingly,
ONOO
 exposure failed to affect Thr308 phosphorylation,
a key residue for insulin-dependent Akt activation (43)
that is not in close contact with any tyrosine residues. On
the other hand, we found that unlike in vitro ONOO

exposure, intralipid infusion in vivo impedes both Ser473
and Thr308 phosphorylation in wild-type mice, while iNOS
genetic deletion only partially and not signiﬁcantly re-
stored Akt Thr308 phosphorylation. This suggests that
iNOS is not implicated in the mechanism leading to
reduced Thr308 phosphorylation in liver of lipid-infused
mice, consistent with the selective effect of ONOO
 on Akt
Ser473 phosphorylation in vitro. Nevertheless, Akt kinase
activity and liver insulin action were fully normalized in
lipid-infused iNOS knockout mice, indicating that only
restoring Akt Ser473 phosphorylation was sufﬁcient to
prevent liver Akt dysfunction in this model of lipid-
induced insulin resistance.
The present results do not rule out S-nitrosylation as an
alternative mechanism negatively regulating insulin signal
transduction in this model of lipid-induced insulin resis-
tance. Indeed, iNOS-mediated S-nitrosylation of cysteine
residues in key insulin signaling intermediates such as
insulin resistance, IRS-1, and Akt has been previously
observed in models of inﬂammation and obesity-related
insulin resistance (28,44). Whether nitrosylation and nitra-
tion of insulin signaling proteins occur simultaneously or
sequentially in different models of insulin resistance
clearly warrants further investigations.
Overall, these data provide genetic evidence that iNOS
is a key factor in the regulation of insulin sensitivity and
hepatic glucose metabolism by FFAs in vivo. Our data
further suggest that iNOS causes hepatic insulin resistance
by impairing insulin signaling through the coordinated
action of three independent mechanisms: by promoting 1)
inhibitory serine phosphorylation of IRS proteins, 2) ty-
rosine nitration of IR and IRS-1/-2, as well as by 3)
directly impairing Akt activity through its tyrosine nitra-
tion. The latter two nitrosative modiﬁcations are poten-
tially triggered by iNOS-linked ONOO
, suggesting that
limitation of ONOO
 generation should be considered as a
potential target for combating insulin resistance in obesity
and metabolic conditions associated with excess lipid
availability.
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